Gastrin-releasing peptide receptor antagonism induces protection from lethal sepsis: Involvement of toll-like receptor 4 signaling

Fabricia Petronilho, Francieli Vuolo, Letícia Selinger Galant, Larissa Constantino, Cristiane Damiani Tomasi, Vinicius Renne Giombelli, Cláudio Teodoro de Souza, Sabrina D. da Silva, Denise Frediani Barbeiro, Francisco Garcia Soriano, Emílio Luiz Streck, Cristiane Ritter, Alfeu Zanotto-Filho, Matheus Augusto Pasquali, Daniel Pens Gelain, José Luiz Rybarczyk-Filho, José Cláudio Fonseca Moreira, Norman L Block, Rafael Roesler, Gilberto SchwartsmannAndrew V Schally, Felipe Dal-Pizzol

Research output: Contribution to journalArticle

13 Citations (Scopus)

Abstract

In sepsis, toll-like receptor (TLR)-4 modulates the migration of neutrophils to infectious foci, favoring bacteremia and mortality. In experimental sepsis, organ dysfunction and cytokines released by activated macrophages can be reduced by gastrin-releasing peptide (GRP) receptor (GRPR) antagonist RC-3095. Here we report a link between GRPR and TLR-4 in experimental models and in sepsis patients. RAW 264.7 culture cells were exposed to lipopolysaccharide (LPS) or tumor necrosis factor (TNF)-α and RC-3095 (10 ng/mL). Male Wistar rats were subjected to cecal ligation and puncture (CLP), and RC-3095 was administered (3 mg/kg, subcutaneously); after 6 h, we removed the blood, bronchoalveolar lavage, peritoneal lavage and lung. Human patients with a clinical diagnosis of sepsis received a continuous infusion with RC-3095 (3 mg/kg, intravenous) over a period of 12 h, and plasma was collected before and after RC-3095 administration and, in a different set of patients with systemic inflammatory response syndrome (SIRS) or sepsis, GRP plasma levels were determined. RC-3095 inhibited TLR-4, extracellular-signal-related kinase (ERK)-1/2, Jun NH2-terminal kinase (JNK) and Akt and decreased activation of activator protein 1 (AP-1), nuclear factor (NF)-αB and interleukin (IL)-6 in macrophages stimulated by LPS. It also decreased IL-6 release from macrophages stimulated by TNF-α. RC-3095 treatment in CLP rats decreased lung TLR-4, reduced the migration of cells to the lung and reduced systemic cytokines and bacterial dissemination. Patients with sepsis and systemic inflammatory response syndrome have elevated plasma levels of GRP, which associates with clinical outcome in the sepsis patients. These findings highlight the role of GRPR signaling in sepsis outcome and the beneficial action of GRPR antagonists in controlling the inflammatory response in sepsis through a mechanism involving at least inhibition of TLR-4 signaling.

Original languageEnglish
Pages (from-to)1209-1219
Number of pages11
JournalMolecular Medicine
Volume18
Issue number8
DOIs
StatePublished - Aug 1 2012

Fingerprint

Bombesin Receptors
Toll-Like Receptor 4
Sepsis
Gastrin-Releasing Peptide
Systemic Inflammatory Response Syndrome
Macrophages
Punctures
Lung
Ligation
Lipopolysaccharides
Tumor Necrosis Factor-alpha
CCAAT-Enhancer-Binding Protein-beta
Cytokines
Peritoneal Lavage
JNK Mitogen-Activated Protein Kinases
Transcription Factor AP-1
Bronchoalveolar Lavage
Bacteremia
Tpi(6)-Leu(13)-psi(CH2NH)-Leu(14)-bombesin (6-14)
Cell Movement

ASJC Scopus subject areas

  • Genetics
  • Molecular Biology
  • Molecular Medicine
  • Genetics(clinical)

Cite this

Petronilho, F., Vuolo, F., Galant, L. S., Constantino, L., Tomasi, C. D., Giombelli, V. R., ... Dal-Pizzol, F. (2012). Gastrin-releasing peptide receptor antagonism induces protection from lethal sepsis: Involvement of toll-like receptor 4 signaling. Molecular Medicine, 18(8), 1209-1219. https://doi.org/10.2119/molmed.2012.00083

Gastrin-releasing peptide receptor antagonism induces protection from lethal sepsis : Involvement of toll-like receptor 4 signaling. / Petronilho, Fabricia; Vuolo, Francieli; Galant, Letícia Selinger; Constantino, Larissa; Tomasi, Cristiane Damiani; Giombelli, Vinicius Renne; de Souza, Cláudio Teodoro; da Silva, Sabrina D.; Barbeiro, Denise Frediani; Soriano, Francisco Garcia; Streck, Emílio Luiz; Ritter, Cristiane; Zanotto-Filho, Alfeu; Pasquali, Matheus Augusto; Gelain, Daniel Pens; Rybarczyk-Filho, José Luiz; Moreira, José Cláudio Fonseca; Block, Norman L; Roesler, Rafael; Schwartsmann, Gilberto; Schally, Andrew V; Dal-Pizzol, Felipe.

In: Molecular Medicine, Vol. 18, No. 8, 01.08.2012, p. 1209-1219.

Research output: Contribution to journalArticle

Petronilho, F, Vuolo, F, Galant, LS, Constantino, L, Tomasi, CD, Giombelli, VR, de Souza, CT, da Silva, SD, Barbeiro, DF, Soriano, FG, Streck, EL, Ritter, C, Zanotto-Filho, A, Pasquali, MA, Gelain, DP, Rybarczyk-Filho, JL, Moreira, JCF, Block, NL, Roesler, R, Schwartsmann, G, Schally, AV & Dal-Pizzol, F 2012, 'Gastrin-releasing peptide receptor antagonism induces protection from lethal sepsis: Involvement of toll-like receptor 4 signaling', Molecular Medicine, vol. 18, no. 8, pp. 1209-1219. https://doi.org/10.2119/molmed.2012.00083
Petronilho, Fabricia ; Vuolo, Francieli ; Galant, Letícia Selinger ; Constantino, Larissa ; Tomasi, Cristiane Damiani ; Giombelli, Vinicius Renne ; de Souza, Cláudio Teodoro ; da Silva, Sabrina D. ; Barbeiro, Denise Frediani ; Soriano, Francisco Garcia ; Streck, Emílio Luiz ; Ritter, Cristiane ; Zanotto-Filho, Alfeu ; Pasquali, Matheus Augusto ; Gelain, Daniel Pens ; Rybarczyk-Filho, José Luiz ; Moreira, José Cláudio Fonseca ; Block, Norman L ; Roesler, Rafael ; Schwartsmann, Gilberto ; Schally, Andrew V ; Dal-Pizzol, Felipe. / Gastrin-releasing peptide receptor antagonism induces protection from lethal sepsis : Involvement of toll-like receptor 4 signaling. In: Molecular Medicine. 2012 ; Vol. 18, No. 8. pp. 1209-1219.
@article{13df7843442e48e19ee364722bce2391,
title = "Gastrin-releasing peptide receptor antagonism induces protection from lethal sepsis: Involvement of toll-like receptor 4 signaling",
abstract = "In sepsis, toll-like receptor (TLR)-4 modulates the migration of neutrophils to infectious foci, favoring bacteremia and mortality. In experimental sepsis, organ dysfunction and cytokines released by activated macrophages can be reduced by gastrin-releasing peptide (GRP) receptor (GRPR) antagonist RC-3095. Here we report a link between GRPR and TLR-4 in experimental models and in sepsis patients. RAW 264.7 culture cells were exposed to lipopolysaccharide (LPS) or tumor necrosis factor (TNF)-α and RC-3095 (10 ng/mL). Male Wistar rats were subjected to cecal ligation and puncture (CLP), and RC-3095 was administered (3 mg/kg, subcutaneously); after 6 h, we removed the blood, bronchoalveolar lavage, peritoneal lavage and lung. Human patients with a clinical diagnosis of sepsis received a continuous infusion with RC-3095 (3 mg/kg, intravenous) over a period of 12 h, and plasma was collected before and after RC-3095 administration and, in a different set of patients with systemic inflammatory response syndrome (SIRS) or sepsis, GRP plasma levels were determined. RC-3095 inhibited TLR-4, extracellular-signal-related kinase (ERK)-1/2, Jun NH2-terminal kinase (JNK) and Akt and decreased activation of activator protein 1 (AP-1), nuclear factor (NF)-αB and interleukin (IL)-6 in macrophages stimulated by LPS. It also decreased IL-6 release from macrophages stimulated by TNF-α. RC-3095 treatment in CLP rats decreased lung TLR-4, reduced the migration of cells to the lung and reduced systemic cytokines and bacterial dissemination. Patients with sepsis and systemic inflammatory response syndrome have elevated plasma levels of GRP, which associates with clinical outcome in the sepsis patients. These findings highlight the role of GRPR signaling in sepsis outcome and the beneficial action of GRPR antagonists in controlling the inflammatory response in sepsis through a mechanism involving at least inhibition of TLR-4 signaling.",
author = "Fabricia Petronilho and Francieli Vuolo and Galant, {Let{\'i}cia Selinger} and Larissa Constantino and Tomasi, {Cristiane Damiani} and Giombelli, {Vinicius Renne} and {de Souza}, {Cl{\'a}udio Teodoro} and {da Silva}, {Sabrina D.} and Barbeiro, {Denise Frediani} and Soriano, {Francisco Garcia} and Streck, {Em{\'i}lio Luiz} and Cristiane Ritter and Alfeu Zanotto-Filho and Pasquali, {Matheus Augusto} and Gelain, {Daniel Pens} and Rybarczyk-Filho, {Jos{\'e} Luiz} and Moreira, {Jos{\'e} Cl{\'a}udio Fonseca} and Block, {Norman L} and Rafael Roesler and Gilberto Schwartsmann and Schally, {Andrew V} and Felipe Dal-Pizzol",
year = "2012",
month = "8",
day = "1",
doi = "10.2119/molmed.2012.00083",
language = "English",
volume = "18",
pages = "1209--1219",
journal = "Molecular Medicine",
issn = "1076-1551",
publisher = "Feinstein Institute for Medical Research",
number = "8",

}

TY - JOUR

T1 - Gastrin-releasing peptide receptor antagonism induces protection from lethal sepsis

T2 - Involvement of toll-like receptor 4 signaling

AU - Petronilho, Fabricia

AU - Vuolo, Francieli

AU - Galant, Letícia Selinger

AU - Constantino, Larissa

AU - Tomasi, Cristiane Damiani

AU - Giombelli, Vinicius Renne

AU - de Souza, Cláudio Teodoro

AU - da Silva, Sabrina D.

AU - Barbeiro, Denise Frediani

AU - Soriano, Francisco Garcia

AU - Streck, Emílio Luiz

AU - Ritter, Cristiane

AU - Zanotto-Filho, Alfeu

AU - Pasquali, Matheus Augusto

AU - Gelain, Daniel Pens

AU - Rybarczyk-Filho, José Luiz

AU - Moreira, José Cláudio Fonseca

AU - Block, Norman L

AU - Roesler, Rafael

AU - Schwartsmann, Gilberto

AU - Schally, Andrew V

AU - Dal-Pizzol, Felipe

PY - 2012/8/1

Y1 - 2012/8/1

N2 - In sepsis, toll-like receptor (TLR)-4 modulates the migration of neutrophils to infectious foci, favoring bacteremia and mortality. In experimental sepsis, organ dysfunction and cytokines released by activated macrophages can be reduced by gastrin-releasing peptide (GRP) receptor (GRPR) antagonist RC-3095. Here we report a link between GRPR and TLR-4 in experimental models and in sepsis patients. RAW 264.7 culture cells were exposed to lipopolysaccharide (LPS) or tumor necrosis factor (TNF)-α and RC-3095 (10 ng/mL). Male Wistar rats were subjected to cecal ligation and puncture (CLP), and RC-3095 was administered (3 mg/kg, subcutaneously); after 6 h, we removed the blood, bronchoalveolar lavage, peritoneal lavage and lung. Human patients with a clinical diagnosis of sepsis received a continuous infusion with RC-3095 (3 mg/kg, intravenous) over a period of 12 h, and plasma was collected before and after RC-3095 administration and, in a different set of patients with systemic inflammatory response syndrome (SIRS) or sepsis, GRP plasma levels were determined. RC-3095 inhibited TLR-4, extracellular-signal-related kinase (ERK)-1/2, Jun NH2-terminal kinase (JNK) and Akt and decreased activation of activator protein 1 (AP-1), nuclear factor (NF)-αB and interleukin (IL)-6 in macrophages stimulated by LPS. It also decreased IL-6 release from macrophages stimulated by TNF-α. RC-3095 treatment in CLP rats decreased lung TLR-4, reduced the migration of cells to the lung and reduced systemic cytokines and bacterial dissemination. Patients with sepsis and systemic inflammatory response syndrome have elevated plasma levels of GRP, which associates with clinical outcome in the sepsis patients. These findings highlight the role of GRPR signaling in sepsis outcome and the beneficial action of GRPR antagonists in controlling the inflammatory response in sepsis through a mechanism involving at least inhibition of TLR-4 signaling.

AB - In sepsis, toll-like receptor (TLR)-4 modulates the migration of neutrophils to infectious foci, favoring bacteremia and mortality. In experimental sepsis, organ dysfunction and cytokines released by activated macrophages can be reduced by gastrin-releasing peptide (GRP) receptor (GRPR) antagonist RC-3095. Here we report a link between GRPR and TLR-4 in experimental models and in sepsis patients. RAW 264.7 culture cells were exposed to lipopolysaccharide (LPS) or tumor necrosis factor (TNF)-α and RC-3095 (10 ng/mL). Male Wistar rats were subjected to cecal ligation and puncture (CLP), and RC-3095 was administered (3 mg/kg, subcutaneously); after 6 h, we removed the blood, bronchoalveolar lavage, peritoneal lavage and lung. Human patients with a clinical diagnosis of sepsis received a continuous infusion with RC-3095 (3 mg/kg, intravenous) over a period of 12 h, and plasma was collected before and after RC-3095 administration and, in a different set of patients with systemic inflammatory response syndrome (SIRS) or sepsis, GRP plasma levels were determined. RC-3095 inhibited TLR-4, extracellular-signal-related kinase (ERK)-1/2, Jun NH2-terminal kinase (JNK) and Akt and decreased activation of activator protein 1 (AP-1), nuclear factor (NF)-αB and interleukin (IL)-6 in macrophages stimulated by LPS. It also decreased IL-6 release from macrophages stimulated by TNF-α. RC-3095 treatment in CLP rats decreased lung TLR-4, reduced the migration of cells to the lung and reduced systemic cytokines and bacterial dissemination. Patients with sepsis and systemic inflammatory response syndrome have elevated plasma levels of GRP, which associates with clinical outcome in the sepsis patients. These findings highlight the role of GRPR signaling in sepsis outcome and the beneficial action of GRPR antagonists in controlling the inflammatory response in sepsis through a mechanism involving at least inhibition of TLR-4 signaling.

UR - http://www.scopus.com/inward/record.url?scp=84870336694&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84870336694&partnerID=8YFLogxK

U2 - 10.2119/molmed.2012.00083

DO - 10.2119/molmed.2012.00083

M3 - Article

C2 - 22735756

AN - SCOPUS:84870336694

VL - 18

SP - 1209

EP - 1219

JO - Molecular Medicine

JF - Molecular Medicine

SN - 1076-1551

IS - 8

ER -